In the last trading session, 1.36 million Iterum Therapeutics Plc (NASDAQ:ITRM) shares changed hands as the company’s beta touched 2.25. With the company’s per share price at $1.40 changed hands at $0.1 or 7.69% during last session, the market valuation stood at $34.24M. ITRM’s last price was a discount, traded about -78.57% off its 52-week high of $2.50. The share price had its 52-week low at $0.71, which suggests the last value was 49.29% up since then. When we look at Iterum Therapeutics Plc’s average trading volume, we note the 10-day average is 2.93 million shares, with the 3-month average coming to 2.36 million.
Analysts gave the Iterum Therapeutics Plc (ITRM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ITRM as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Iterum Therapeutics Plc’s EPS for the current quarter is expected to be -0.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iterum Therapeutics Plc (NASDAQ:ITRM) trade information
Instantly ITRM was in green as seen at the end of in last trading. With action 14.75%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -28.93%, with the 5-day performance at 14.75% in the green. However, in the 30-day time frame, Iterum Therapeutics Plc (NASDAQ:ITRM) is 50.55% up. Looking at the short shares, we see there were 0.21 million shares sold at short interest cover period of 1.16 days.
Iterum Therapeutics Plc (ITRM) estimates and forecasts
Data shows that the Iterum Therapeutics Plc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -13.04% over the past 6 months, a 59.80% in annual growth rate that is considerably higher than the industry average of 18.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.62%. The 2024 estimates are for Iterum Therapeutics Plc earnings to increase by 68.93%.
ITRM Dividends
Iterum Therapeutics Plc is expected to release its next quarterly earnings report in December.
Iterum Therapeutics Plc (NASDAQ:ITRM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.81% of Iterum Therapeutics Plc shares while 3.05% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 3.10%. There are 3.05% institutions holding the Iterum Therapeutics Plc stock share, with BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 0.0004% of the shares, roughly 66.0 ITRM shares worth $76.0.
ANCORA ADVISORS, LLC holds the second largest percentage of outstanding shares.
